Safety check for duchenne drug: can patients tolerate it Long-Term?
NCT ID NCT01247207
Summary
This study aimed to check the long-term safety of a drug called ataluren in people with Duchenne muscular dystrophy caused by a specific 'nonsense' genetic mutation. It involved 270 participants who had already taken ataluren in a previous trial, or were siblings of those participants. The goal was to monitor patients for side effects and health changes while they continued taking the drug until it became commercially available or they entered another study.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alberta Children's Hospital
Calgary, Alberta, Canada
-
British Columbia Children's Hospital
Vancouver, British Columbia, Canada
-
CHU de Québec - Université Laval
Québec, Canada
-
Child Neurology Center of NW Florida NW
Gulf Breeze, Florida, 32561, United States
-
Children's Hospital Colorado - Center for Cancer and Blood Disorders
Aurora, Colorado, 80045, United States
-
Children's Hospital of Boston/Harvard Medical School
Boston, Massachusetts, 02115, United States
-
Children's Hospital of East Ontario
Ottawa, Ontario, Canada
-
Children's Hospital of Los Angeles
Los Angeles, California, 90027, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Children's Hospital of the King's Daughters
Norfolk, Virginia, 23507, United States
-
Childrens Medical Center Dallas
Dallas, Texas, 75207, United States
-
Cincinnati Childrens Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Columbia University Pediatric Neuromuscular Center
New York, New York, 10032, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
London Health Sciences Centre
London, Ontario, Canada
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
-
Phoenix Childrens Hospital
Phoenix, Arizona, 85016, United States
-
Rare Disease Research, LLC
Atlanta, Georgia, 30329, United States
-
Rush Univ Medical Center
Chicago, Illinois, 60612, United States
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
-
Shriners Hospital for Children-Portland
Portland, Oregon, 97239, United States
-
Stanford University
Palo Alto, California, 94304, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
-
UCLA
Los Angeles, California, 90095, United States
-
University of CA, San Francisco-Benioff Children's Hospital
San Francisco, California, 94158, United States
-
University of California-Davis
Sacramento, California, 95817, United States
-
University of Iowa Children's Hospital
Iowa City, Iowa, 52242, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 16148, United States
-
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229, United States
-
University of Utah
Salt Lake City, Utah, 84112, United States
-
Washington University Medical School
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.